Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC
Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is an openlabel，single center
，non-randomized ，Single Arm Exploratory Study . This clinical study is an
investigator-initiated clinical trial（IIT). The objective of this study is to evaluate the
efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 and
chemotherapy in patients with Locally Advanced Esophageal Squamous Cell Carcinomas。
Phase:
N/A
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital